Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option to...
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option to...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.